menu
    • menu
    [{"orgOrder":0,"company":"University of Iowa Pharmaceuticals","sponsor":"Shuttle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"University of Iowa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Iowa Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Iowa Pharmaceuticals \/ University of Iowa Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by University of Iowa Pharmaceuticals

    Menu

    University of Iowa Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Iowa Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            University of Iowa Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropidoxuridine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Shuttle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxur...

                            Details : The agreement aims at the formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. Ropidoxuridine is used to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells.

                            Product Name : IPdR Prodrug

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 09, 2023

                            Lead Product(s) : Ropidoxuridine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Shuttle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth